Bruno Geloneze

Prof. Dr. Bruno Geloneze

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2009 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
BGBruno Geloneze
Bruno Geloneze
AVAna Carolina Junqueira Vasques
Ana Carolina Junqueira Vasques
CSChristiane França Camargo Stabe
Christiane França Camargo Stabe
JPJosé Carlos Pareja
José Carlos Pareja
LRLina Enriqueta Frandsen Paez de Lima Rosado
Lina Enriqueta Frandsen Paez de Lima Rosado
MTMarcos Antonio Tambascia
Marcos Antonio Tambascia
OBJECTIVE: To investigate cut-off values for HOMA1-IR and HOMA2-IR to identify insulin resistance (IR) and metabolic syndrome (MS), and to assess the association of the indexes with components of the MS. METHODS: Nondiabetic subjects from the Brazilian Metabolic Syndrome Study were studied (n = 1,203, 18 to 78 years). The cut-off values for IR were determined from the 90th percentile in the healthy group (n = 297) and, for MS, a ROC curve was generated for the total sample. RESULTS: In the healthy group, HOMA-IR indexes were associated with central obesity, triglycerides and total cholesterol (p < 0.001). The cut-off values for IR were: HOMA1-IR > 2.7 and HOMA2-IR > 1.8; and, for MS were: HOMA1-IR > 2.3 (sensitivity: 76.8%; specificity: 66.7%) and HOMA2-IR > 1.4 (sensitivity: 79.2%; specificity: 61.2%). CONCLUSION: The cut-off values identified for HOMA1-IR and HOMA2-IR indexes have a clinical and epidemiological application for identifying IR and MS in Westernized admixtured multi-ethnic populations.

12 May 2009 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
BGBruno Geloneze
Bruno Geloneze
SGSylka R. Geloneze
Sylka R. Geloneze
CFCarla Fiori
Carla Fiori
CSChristiane Stabe
Christiane Stabe
MTMarcos A. Tambascia
Marcos A. Tambascia
JPJose Carlos Pareja
Jose Carlos Pareja

27 January 2021 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
Maria Cristina IzarMaria Cristina Izar
Maria Cristina Izar
ALAna Maria Lottenberg
Ana Maria Lottenberg
VGViviane Zorzanelli Rocha Giraldez
Viviane Zorzanelli Rocha Giraldez
RSRaul D Santos
Raul D Santos
RMRoberta Marcondes Machado
Roberta Marcondes Machado
VMValéria Arruda Machado
Valéria Arruda Machado
Lista de Siglas ACC – American College of Cardiology Acetil-CoA – acetilcoenzima A […] Posicionamento sobre o Consumo de Gorduras e Saúde Cardiovascular – 2021 Lista de Siglas ACC – American College of Cardiology Acetil-CoA – acetilcoenzima A […] Posicionamento sobre o Consumo de Gorduras e Saúde Cardiovascular – 2021

1 July 2012 in Annals of Surgery
Verified
Journal Article
Closed access
BGBruno Geloneze
Bruno Geloneze
SGSylka Rodovalho Geloneze
Sylka Rodovalho Geloneze
ECElinton Chaim
Elinton Chaim
FHFernanda Filgueira Hirsch
Fernanda Filgueira Hirsch
AFAna Claudia Felici
Ana Claudia Felici
JPJosé Carlos Pareja
José Carlos Pareja
To compare duodenal-jejunal bypass (DJB) with standard medical care in nonobese patients with type 2 diabetes and evaluate surgically induced endocrine and metabolic changes. Eighteen patients submitted to a DJB procedure met the following criteria: overweight, diabetes diagnosis less than 15 years, current insulin treatment, residual β-cell function, and absence of autoimmunity. Patients who refused surgical treatment received standard medical care (control group). At baseline, 3, 6, and 12 months after surgery, insulin sensitivity and production of glucagon-like peptide-1 and glucose-insulinotropic polypeptide were assessed during a meal tolerance test. Fasting adipocytokines and dipeptidyl-peptidase-4 concentrations were measured. The mean age of the patients was 50 (5) years, time of diagnosis: 9 (2) years, time of insulin usage: 6 (5) months, fasting glucose: 9.9 (2.5) mmol/dL, and HbA1c (glycosylated hemoglobin) level: 8.9% (1.2%). Duodenal-jejunal bypass group showed greater reductions in fasting glucose (22% vs 6% in control group, P < 0.05) and daily insulin requirement (93% vs 15%, P < 0.01). Twelve patients from DJB group stopped using insulin and showed improvements in insulin sensitivity and β-cell function (P < 0.01), and reductions in glucose-insulinotropic polypeptide levels (P < 0.001), glucagon during the first 30 minutes after meal (P < 0.05), and leptin levels (P < 0.05). Dipeptidyl-peptidase-4 levels increased after surgery (P < 0.01), but glucagon-like peptide-1 levels did not change. Duodenal-jejunal bypass improved insulin sensitivity and β-cell function and reduced glucose-insulinotropic polypeptide, leptin, and glucagon production. Hence, DJB resulted in better glycemic control and reduction in insulin requirement but DJB did not result in remission of diabetes.

23 February 2017 in Drugs
Verified
Journal Article
Open access
PDF file
BGBruno Geloneze
Bruno Geloneze
JLJosé Carlos de Lima-Júnior
José Carlos de Lima-Júnior
LVLício A. Velloso
Lício A. Velloso
The complexity of neural circuits that control food intake and energy balance in the hypothalamic nuclei explains some of the constraints involved in the prevention and treatment of obesity. Two major neuronal populations present in the arcuate nucleus control caloric intake and energy expenditure: one population co-expresses orexigenic agouti-related peptide (AgRP) and neuropeptide Y and the other expresses the anorexigenic anorectic neuropeptides proopiomelanocortin and cocaine- and amphetamine-regulated transcript (POMC/CART). In addition to integrating signals from neurotransmitters and hormones, the hypothalamic systems that regulate energy homeostasis are affected by nutrients. Fat-rich diets, for instance, elicit hypothalamic inflammation (reactive activation and proliferation of microglia, a condition named gliosis). This process generates resistance to the anorexigenic hormones leptin and insulin, contributing to the genesis of obesity. Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have increasingly been used to treat type 2 diabetes mellitus. One compound (liraglutide) was recently approved for the treatment of obesity. Although most studies suggest that GLP-1RAs promote weight loss mainly due to their inhibitory effect on food intake, other central effects that have been described for native GLP-1 and some GLP-1RAs in rodents and humans encourage future clinical trials to explore additional mechanisms that potentially underlie the beneficial effects observed with this drug class. In this article we review the most relevant data exploring the mechanisms involved in the effects of GLP-1RAs in the brain–adipocyte axis.

4 August 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BVBrunna Sullara Vilela
Brunna Sullara Vilela
AVAna Carolina Junqueira Vasques
Ana Carolina Junqueira Vasques
RCRoberta Soares Lara Cassani
Roberta Soares Lara Cassani
AFAdriana Costa e Forti
Adriana Costa e Forti
JPJosé Carlos Pareja
José Carlos Pareja
BGBruno Geloneze
Bruno Geloneze
The major adverse consequences of obesity are associated with the development of insulin resistance (IR) and adiposopathy. The Homeostasis Model Assessment-Adiponectin (HOMA-AD) was proposed as a modified version of the HOMA1-IR, which incorporates adiponectin in the denominator of the index. To evaluate the performance of the HOMA-AD index compared with the HOMA1-IR index as a surrogate marker of IR in women, and to establish the cutoff value of the HOMA-AD. The Brazilian Metabolic Syndrome Study (BRAMS) is a cross-sectional multicenter survey. The data from 1,061 subjects met the desired criteria: 18–65 years old, BMI: 18.5–49.9 Kg/m² and without diabetes. The IR was assessed by the indexes HOMA1-IR and HOMA-AD (total sample) and by the hyperglycemic clamp (n = 49). Metabolic syndrome was defined using the IDF criteria. For the IR assessed by the clamp, the HOMA-AD demonstrated a stronger coefficient of correlation (r = -0.64) compared with the HOMA1-IR (r = -0.56); p < 0.0001. In the ROC analysis, compared with the HOMA1-IR, the HOMA-AD showed higher values of the AUC for the identification of IR based on the clamp test (AUC: 0.844 vs. AUC: 0.804) and on the metabolic syndrome (AUC: 0.703 vs. AUC: 0.689), respectively; p < 0.001 for all. However, the pairwise comparison did not show evidence of superiority for the HOMA-AD in comparison with the HOMA1-IR in the diagnosis of IR and metabolic syndrome (p > 0.05). The optimal cutoff identified for the HOMA-AD for the diagnosis of IR was 0.95. The HOMA-AD index was demonstrated to be a useful surrogate marker for detecting IR among adult women and presented a similar performance compared with the HOMA1-IR index. These results may assist physicians and researchers in determining which method to use to evaluate IR in light of the available facilities.